J
James Dirk Iglehart
Researcher at Brigham and Women's Hospital
Publications - 19
Citations - 1459
James Dirk Iglehart is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 11, co-authored 19 publications receiving 1366 citations. Previous affiliations of James Dirk Iglehart include Harvard University.
Papers
More filters
Journal ArticleDOI
Transformation of Different Human Breast Epithelial Cell Types Leads to Distinct Tumor Phenotypes
Tan A. Ince,Andrea L. Richardson,Andrea L. Richardson,George W. Bell,Maki Saitoh,Samuel Godar,Antoine E. Karnoub,James Dirk Iglehart,Robert A. Weinberg +8 more
TL;DR: Compared tumors derived from two different normal human mammary epithelial cell populations, one of which was isolated using a new culture medium, found that the pre-existing differences between BPECs and HMECs strongly influence the phenotypes of their transformed derivatives.
Journal ArticleDOI
Recursive SVM feature selection and sample classification for mass-spectrometry and microarray data
Xuegong Zhang,Xin Lu,Qian Shi,Xiu-qin Xu,Hon-chiu Eastwood Leung,Lyndsay Harris,James Dirk Iglehart,Alexander Miron,Jun Liu,Wing Hung Wong +9 more
TL;DR: The proposed R-SVM method is suitable for analyzing noisy high-throughput proteomics and microarray data and it outperforms SVM-RFE in the robustness to noise and in the ability to recover informative features.
Journal ArticleDOI
Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancers.
Zhigang C. Wang,Ming Lin,Lee-Jen Wei,Cheng Li,Alexander Miron,Gabriella Lodeiro,Lyndsay Harris,Sridhar Ramaswamy,Sridhar Ramaswamy,David M. Tanenbaum,Matthew Meyerson,James Dirk Iglehart,Andrea L. Richardson +12 more
TL;DR: It is found that breast cancers were highly heterogeneous, with the proportion of LOH ranging widely from 0.3% to >60% of heterozygous markers, and finding unique LOH patterns in different groups of breast cancer adds confidence to newer schemes of molecular classification.
Journal ArticleDOI
Breast surgery in stage IV breast cancer: impact of staging and patient selection on overall survival
Andrea C. Bafford,Harold J. Burstein,Harold J. Burstein,Christina R. Barkley,Barbara L. Smith,Stuart R. Lipsitz,James Dirk Iglehart,James Dirk Iglehart,Eric P. Winer,Mehra Golshan,Mehra Golshan +10 more
TL;DR: Breast surgery is associated with improved survival in stage IV breast cancer, however, in the experience, this benefit is only realized among patients operated on before diagnosis of metastatic disease and is likely a consequence of stage migration bias.
Journal ArticleDOI
NCCN Task Force Report: Estrogen receptor and progesterone receptor testing in breast cancer by immunohistochemistry
D. Craig Allred,Robert W. Carlson,Donald A. Berry,Harold J. Burstein,Stephen B. Edge,Lori J. Goldstein,Allen M. Gown,M. Elizabeth H. Hammond,James Dirk Iglehart,Susan Moench,Lori J. Pierce,Peter M. Ravdin,Stuart J. Schnitt,Antonio C. Wolff +13 more
TL;DR: ER is a strong predictor of response to endocrine therapy and priority should be given to improve the quality of IHC testing methodologies, and all laboratories performing IHC assays of hormone receptors in breast cancer should follow additional quality control and assurance measures.